Nalaganje...

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent with its mechanism of action, elagolix exhibited dose‐dependent...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Transl Sci
Main Authors: Stodtmann, Sven, Nader, Ahmed, Polepally, Akshanth R., Suleiman, Ahmed A., Winzenborg, Insa, Noertersheuser, Peter, Ng, Juki, Mostafa, Nael M., Shebley, Mohamad
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2021
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301592/
https://ncbi.nlm.nih.gov/pubmed/33963686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.13040
Oznake: Označite
Brez oznak, prvi označite!